 |
This
table has been provided as a cross reference from the information
included in this Annual Report to the requirements of Form 20-F.
Cautionary factors that may affect future results
Cautionary Statements under the US Private Securities Litigation Reform Act of 1995
The Group’s Annual Report and Accounts and its period reports filed with
the US Securities and Exchange Commission (the ‘Commission’), including this Annual Report on Form 20-F for the year ended 31st
December 2000 (the ‘2000 Form 20-F’), contain, and written information released, or oral statements made to the public in the future
by or on behalf of the Group may contain, forward-looking statements. Forward-looking statements give the Group’s current expectations
or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’,
‘plan’, ‘believe’, and other words and terms of similar meaning in connection with any discussion of future operating
or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future
performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings,
and financial results.
Any or all of the Group’s forward-looking statements in the 2000 Form 20-F, in reports filed with the Commission, or in any other public
statements the Group makes, may turn out to be incorrect. They can be affected by inappropriate or inaccurate assumptions the Group might
use as a basis for such forward-looking statements or by known or unknown risks and uncertainties. Many factors mentioned in the discussion
of the Group’s business in the 2000 Form 20-F will be important in determining future results. Consequently, no forward-looking statement
should be viewed as or can be guaranteed. Actual future results may vary materially.
The Group undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events
or otherwise. Investors should also note the cautionary discussion
of risks and uncertainties relevant to the Group’s business
set out under Risk
factors. This discussion is provided as permitted by the US
Private Securities Litigation Reform Act of 1995.
Related party transactions
GlaxoSmithKline has a 27 per cent interest in Quest Diagnostics Inc. The activities of Quest are not part of the company’s core business,
and the interest is held only as an investment.
Material contracts
The Boards of Glaxo Wellcome plc and SmithKline Beecham plc announced on 17th January 2000 the terms of an agreement for the proposed merger
of the two companies. The merger was implemented by way of a scheme of arrangement on 27th December 2000, on which date GlaxoSmithKline plc
acquired the whole of the issued share capital of Glaxo Wellcome plc and SmithKline Beecham plc.
On 18th January 2001 GlaxoSmithKline completed the acquisition of Block Drug Company Inc, a manufacturer of toothpaste and other oral healthcare
and consumer products, for US$1,240 million (£832 million).
Documents on display
Documents referred to in this Annual Report are available for inspection at the Registered Office of the company.
|
